(Q37697782)

22 August 2017

1 reference

title

Cethromycin: a promising new ketolide antibiotic for respiratory infections (English)

1 reference

22 August 2017

1 reference

ChEBI release 2020-05-28

Sally Rafie

1

1 reference

22 August 2017

Conan MacDougall

series ordinal

2

1 reference

22 August 2017

Charles L James

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

30

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

290-303

1 reference

The cost of treating community-acquired pneumonia.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

The FDA and the case of Ketek

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Induction of erm(C) expression by noninducing antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Short peptides conferring resistance to macrolide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

The ketolide antibiotic ABT-773 is a specific inhibitor of translation and 50S ribosomal subunit formation in Streptococcus pneumoniae cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Ketolides: the future of the macrolides?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

The chemistry of protein synthesis and voyage through the ribosomal tunnel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Peptide-mediated macrolide resistance reveals possible specific interactions in the nascent peptide exit tunnel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Ketolide resistance conferred by short peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Drug interactions during therapy with three major groups of antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Erythromycin resistance by ribosome modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Prevalence of macrolide and tetracycline resistance mechanisms in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro bactericidal activity of ABT-773 and amoxicillin against erythromycin-susceptible and -resistant strains of Streptococcus pyogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Expression of the mef(E) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Susceptibility of 170 isolates of the USA300 clone of MRSA to macrolides, clindamycin and the novel ketolide cethromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Antipneumococcal activity of ABT-773 compared to those of 10 other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro activity of the ketolide ABT-773

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Ribosome affinity and the prolonged molecular postantibiotic effect of cethromycin (ABT-773) in Haemophilus influenzae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Comparative in vitro activity of ABT-773, a novel antibacterial ketolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Telithromycin-induced digoxin toxicity and electrocardiographic changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.290

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.3.290

1 reference

22 August 2017

1 reference